The Neuroplatform: Towards a Comprehensive Mechanistic QSP Model of Alzheimer’s Disease for Supporting Drug Discovery and Development
With over 55 million people diagnosed worldwide, Alzheimer's disease presents a significant public health challenge,…
CertaraApril 29, 2024
Multi-phase multi-layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin
Physiologically-based pharmacokinetic models combine knowledge about physiology, drug product properties, such as physicochemical parameters, absorption,…
CertaraApril 26, 2024
Explore the World of Endogenous Biomarkers with Simcyp™!
Endogenous biomarkers play a pivotal role in comprehending drug-body interactions, shaping drug development, and propelling…
CertaraApril 26, 2024
Latest PBPK Modeling Platform Advances Drug Development
In the ever-evolving pharmaceutical landscape, advancing drug development requires innovative tools that seamlessly integrate science…
CertaraApril 23, 2024
Certara Announces Inaugural Client Conference with Keynote by Dr. Scott Gottlieb
Agenda features discussion of life sciences industry trends, business value of model-informed drug development strategies,…
CertaraApril 18, 2024
The Challenges and Opportunities of Rare Disease Drug Development
This whitepaper by drug development experts reflect on some of these challenges and opportunities in…
CertaraApril 18, 2024
